Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/181687PREPARATION METHOD FOR AND INTERMEDIATE OF DRUG-LINKER FOR ANTIBODY DRUG CONJUGATE MC-MMAF
WO 17.09.2020
Int.Class C07K 5/062
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
06Dipeptides
062the side chain of the first amino acid being acyclic, e.g. Gly, Ala
Appl.No PCT/CN2019/092950 Applicant LEVENA BIOPHARMA CO., LTD. Inventor XU, Zhe
A preparation method for and an intermediate of a drug-linker for an antibody drug conjugate MC-MMAF. The reaction activity of the N-terminus is improved, so that the occurrence of a racemic reaction is effectively controlled. The toxin MMAF is not directly used and a fragment peptide having low toxicity is used, so that an operation difficulty in mass production is reduced. No reverse-phase preparation is required so that the operations are simple.
2.WO/2020/181837METHOD FOR RESCUING INFLUENZA VIRUS AND COMPOSITION THEREFOR
WO 17.09.2020
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2019/121905 Applicant ZHEJIANG SENWEI BIOPHARMACEUTICAL DEVELOPMENT CO., LTD. Inventor DAI, Dongsheng
Provided are a new method for rescuing an influenza virus and a composition therefor. The method comprises providing a host cell stably integrated with and expressing influenza virus PA, PB1, PB2 and NP genes, and introducing an influenza virus rescue system in which a stop codon is introduced into the PA, PB1, PB2 and NP genes respectively into the host cell to achieve virus rescue. The produced virus particles can be used as a live attenuated influenza vaccine, which is characterized in that, since the genes encoding the related proteins are mutated, it has no replication and proliferation ability in human and normal animal cells, and replication and proliferation can be achieved only in the host cells constructed above and it can fully stimulate the body immunity and effectively protect the body while ensuring the safety.
3.WO/2020/182197LIQUID COMPOSITION COMPRISING ANTIBODY OF HUMAN INTERLEUKIN-4 RECEPTOR ALPHA
WO 17.09.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2020/079120 Applicant SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. Inventor ZHENG, Wei
The present invention provides a liquid composition comprising an antibody of human interleukin-4 receptor alpha. The liquid composition comprises the antibody at a concentration of 50-200 mg/ml; and a buffer, a protectant, and a surfactant as adjuvants. The liquid composition has a pH of 5.4-6.4.
4.WO/2020/182857TRANSCRIPTION FACTOR-MEDIATED PROMOTION OF DIRECT SOMATIC EMBRYOGENESIS
WO 17.09.2020
Int.Class A01H 4/00
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
HNEW PLANTS OR PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
4Plant reproduction by tissue culture techniques
Appl.No PCT/EP2020/056457 Applicant PERPETUUM CROPSCIENCE BVBA Inventor HOFENK, Jeroen
A recombinant protein for use in a liquid culture medium for photo-autotrophic micropropagation of Cannabis Sativa L. is disclosed. The recombinant protein comprises a fusion of a growth induction part and a uptake enhancement part. The growth induction part comprises an Arabinogalactan protein and/or a plant transcription factor associated with plant growth and development. The uptake enhancement part comprises a cell penetrating peptide sequence and a nuclear localization signal encoded by the peptide sequence SEQ ID NO 1.
5.WO/2020/183147IMMUNOTHERAPY COMBINED WITH AN ANTI-CD38 ANTIBODY
WO 17.09.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/GB2020/050567 Applicant AUTOLUS LIMITED Inventor PEDDAREDDIGARI, Vijay
The present invention relates to the use of an anti-CD38 antibody in a subject undergoing immunotherapy wherein the anti-CD38 antibody is administered before and/or after immunotherapy.
6.WO/2020/185627HUMAN GUT MICROBIOME-DERIVED BIOSYNTHETIC ENZYMES FOR PRODUCTION OF FATTY ACID AMIDES
WO 17.09.2020
Int.Class C12P 1/04
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
1Preparation of compounds or compositions, not provided for in groups C12P3/-C12P39/121; General processes for the preparation of compounds or compositions by using microorganisms or enzymes
04by using bacteria
Appl.No PCT/US2020/021578 Applicant MASSACHUSETTS INSTITUTE OF TECHNOLOGY Inventor VOIGT, Christopher, A.
Disclosed herein, in some embodiments, are vectors encoding biosynthetic enzymes from gut microbiome-derived bacterium (e.g., Clostridia enzymes), engineered cells comprising the vectors, and methods of using biosynthetic enzymes from gut microbiome- derived bacterium (e.g., Clostridia enzymes) to produce fatty acid amides.
7.WO/2020/185917SODIUM FLUORESCEIN AS A REVERSAL AGENT FOR AN ANTI-FLUORESCEIN CAR T CELLS AND FLUORESCEIN-PHOSPHOLIPID-ETHERS OR PROFLUORESCEIN-PHOSPHOLIPID-ETHERS
WO 17.09.2020
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2020/022130 Applicant SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) Inventor JENSON, Michael C.
Some embodiments of the methods and compositions provided herein relate to modulating signaling of anti-hapten CAR T cells, such as anti-fluorescein CAR T cells, by the use or administration of an unconjugated hapten, such as unconjugated fluorescein or a salt or derivative thereof.
8.WO/2020/181376TSG-6 ANTIBODIES AND USES THEREFOR
WO 17.09.2020
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/CA2020/050321 Applicant UNIVERSITY HEALTH NETWORK Inventor BROKX, Richard
The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
9.WO/2020/181686PREPARATION METHOD FOR DRUG-LINKER MC-MMAF USED FOR ANTIBODY DRUG CONJUGATES AND INTERMEDIATE THEREOF
WO 17.09.2020
Int.Class C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
Appl.No PCT/CN2019/092948 Applicant LEVENA BIOPHARMA CO., LTD. Inventor XU, Zhe
The present invention provides a preparation method for a drug-linker MC-MMAF used for antibody drug conjugates and an intermediate thereof. The preparation method of the present invention improves the N-terminal reactivity and thus effectively controls the racemization reaction. A compound having low toxicity is used instead of toxin MMAF so as to reduce the operation difficulty in mass production. No reverse phase preparation is required, therefore the operation is simple.
10.WO/2020/181756METHOD FOR IMPROVING BIOCOUPLING EFFICIENCY BETWEEN PROTEIN AND NUCLEIC ACID BASED ON α-HELIX HANDLE
WO 17.09.2020
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Appl.No PCT/CN2019/107289 Applicant NANKAI UNIVERSITY Inventor YU, Zhongbo
Provided is a method for improving the biocoupling efficiency between a protein and a nucleic acid based on an α-helix handle. The method comprises designing a handle H-tag carrying an unnatural amino acid, then constructing a fusion recombinant expression plasmid containing the H-tag and a protein to be tested, expressing and purifying a fusion recombinant protein containing the unnatural amino acid in the H-tag, and finally subjecting the unnatural amino acid in the H-tag of the fusion protein and a coupling group on a nucleic acid substrate to efficient connection by means of click chemistry. The method uses an α-helix handle to provide controllable protein surface reaction conditions for an unnatural amino acid, and avoids a complex structure, charges and polar nano environment on the surface of the protein to be tested, thereby achieving the target of the efficient connection of a protein and a nucleic acid by means of click chemistry.